JUL 1·SEC EDGARLow
Rice William G. sold (to issuer) $1.1M of APTOF
Rice William G. (Chair, President & CEO) sold (to issuer) 613,252 shares of Aptose Biosciences Inc. (APTOF) at $1.72 ($1.05M total) on 2026-06-30.
StockOTC · US · USDHealthcare · Biotechnology
$APTOF
Aptose Biosciences Inc.
Price · $APTOFvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $APTOF in the last 7 days.
Insider · 30dAll trades →
No SEC Form 4 filings for $APTOF in the last 30 days.
See all $APTOF insider activity →Top stories · $APTOFMore →
JUN 30·SEC EDGAR 8-K
Aptose Biosciences Inc. (APTOF): Completion of Acquisition or Disposition of Assets
Aptose Biosciences Inc. (APTOF) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K false 0000882361 0000882361 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30,
NOV 19·Benzinga
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical - Aptose Biosciences (OTC:APTOF)
SAN DIEGO and TORONTO, Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Aptose Biosciences Inc. ( "Aptose" or the "Company" ) ( TSX:APS, OTC:APTOF ) and Hanmi Pharmaceutical Co. Ltd. ( "Hanmi" ) today announced that Aptose, Hanmi and HS North America Ltd., a wholly owned subsidiary of Hanmi ( "Hanmi ...
APTOF sentiment & insider activity
Recent APTOF coverage spans financial news, insider activity and mergers & acquisitions.
What's driving APTOF
This is an insider sale to the issuer (buyback/issuer transaction code D), not a new operating or regulatory catalyst.
Deal close removes equity optionality and should drive APTOF toward deal-consideration mechanics; delisting timing can affect liquidity and spreads.
The announced acquisition by Hanmi Pharmaceutical is likely to be viewed positively by investors, potentially leading to an upward movement in APTOF's stock price.
Aptose Biosciences reports that its drug Tuspetinib, when combined with standard AML treatments, achieved complete remission responses exceeding expectations in a clinical trial. This positive data could potentially enhance investor confidence in the company's prospects.
Aptose Biosciences announced a deferral of its interest payment, indicating potential liquidity challenges or strategic financial management. The company's somewhat-bullish sentiment suggests cautious optimism among investors.
alphai scores every news story that mentions APTOF with an AI model for sentiment and relevance, and aggregates insider trades from Aptose Biosciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $APTOF
Score
Rice William G. sold (to issuer) $1.1M of APTOF
Rice William G. (Chair, President & CEO) sold (to issuer) 613,252 shares of Aptose Biosciences Inc. (APTOF) at $1.72 ($1.05M total) on 2026-06-30.
1 min readAptose Biosciences Inc. (APTOF): Completion of Acquisition or Disposition of Assets
Aptose Biosciences Inc. (APTOF) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K false 0000882361 0000882361 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30,
2 min read
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical - Aptose Biosciences (OTC:APTOF)
SAN DIEGO and TORONTO, Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Aptose Biosciences Inc. ( "Aptose" or the "Company" ) ( TSX:APS, OTC:APTOF ) and Hanmi Pharmaceutical Co. Ltd. ( "Hanmi" ) today announced that Aptose, Hanmi and HS North America Ltd., a wholly owned subsidiary of Hanmi ( "Hanmi ...
2 min readAptose's Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML - Aptose Biosciences (OTC:APTOF)
Addition of TUS to VEN+AZA achieves CR/CRh responses in all ( 6/6, 100% ) patients treated at the higher dose levels of 80 mg and 120 mg TUS, exceeding the 66% rate expected from VEN+AZA alone CR/CRh responses in 7/8 ( 88% ) FLT3 wildtype AML, representing 70% of AML population
2 min read
Aptose Announces Deferral of Interest Payment - Aptose Biosciences (OTC:APTOF)
SAN DIEGO and TORONTO, June 30, 2025 ( GLOBE NEWSWIRE ) -- Aptose Biosciences Inc. ( "Aptose" or the "Company" ) APSAPTOF, a clinical-stage precision oncology company developing a tuspetinib ( TUS ) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia ...
3 min readAptose Announces Deferral of Interest Payment
SAN DIEGO and TORONTO, June 30, 2025 ( GLOBE NEWSWIRE ) -- Aptose Biosciences Inc. ( "Aptose" or the "Company" ) ( TSX: APS.
2 min readAptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
Aptose and Hanmi Pharmaceutical Enter New Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for ...
2 min readAptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - Aptose Biosciences (OTC:APTOF)
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML AML patients with diverse mutations, including TP53-mutated/CK and FLT3-wildtype, safely achieved complete remissions and MRD negativity
2 min readAptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the ...
2 min read